Table 2. Meta-analyses results of the association between germline HOXB13 p.Gly84Glu mutation and cancer risk.

Variables	No.	Sample size	Pheterogeneity	Analyzing model	OR	95% CI	P value
Total	25	145,257	<0.001	Random	2.872	2.121, 3.888	<0.001
Cancer type
Prostate cancer	19	130,795	<0.001	Random	3.248	2.313, 4.560	<0.001
Breast cancer	3	9,423	0.958	Fixed	1.423	0.774, 2.615	0.256
Colotrectal cancer	3	5,039	0.205	Fixed	2.458	0.978, 6.177	0.056
Ethnicity
Caucasians	21	144,007	<0.001	Random	2.673	1.920, 3.720	<0.001
Mixed decedents	4	12,507	0.362	Fixed	4.164	2.226, 7.790	<0.001
Genotype method
TaqMan	10	46,126	0.149	Fixed	3.649	2.728, 4.880	<0.001
Sanger sequencing	2	4,420	0.201	Fixed	3.862	1.110, 13.441	0.034
MassARRAY iPLEX	4	13,842	0.201	Fixed	2.956	2.337, 3.740	<0.001
Illumina SNP chips	6	72,039	0.135	Fixed	3.934	2.479, 6.245	<0.001
Complex methods	3	8,830	0.067	Fixed	1.119	0.784, 1.597	0.537
Source of control
Hospital based -HB	14	112,986	0.155	Fixed	3.363	2.449, 4.619	<0.001
Population based -PB	5	17,670	0.481	Fixed	3.196	2.234, 4.573	<0.001
PB/HB	4	11,494	0.001	Random	2.378	0.814, 6.952	0.113
Family based -FB	1	443	—	Fixed	2.015	1.286, 3.156	0.002
HB/FB	1	2,664	—	Fixed	4.168	1.235, 14.062	0.021

OR, Odds ratio; 95% CI, 95% confidence interval.